GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Piotroski F-Score

NEO (NeoGenomics) Piotroski F-Score : 6 (As of Dec. 12, 2024)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeoGenomics has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for NeoGenomics's Piotroski F-Score or its related term are showing as below:

NEO' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of NeoGenomics was 8. The lowest was 1. And the median was 4.


NeoGenomics Piotroski F-Score Historical Data

The historical data trend for NeoGenomics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Piotroski F-Score Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 3.00 2.00 2.00 4.00

NeoGenomics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.00 5.00 6.00 6.00

Competitive Comparison of NeoGenomics's Piotroski F-Score

For the Diagnostics & Research subindustry, NeoGenomics's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Piotroski F-Score Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was -14.326 + -27.061 + -18.642 + -17.699 = $-77.7 Mil.
Cash Flow from Operations was 17.784 + -25.915 + 13.892 + 9.246 = $15.0 Mil.
Revenue was 155.552 + 156.24 + 164.502 + 167.824 = $644.1 Mil.
Gross Profit was 67.588 + 65.469 + 72.494 + 74.88 = $280.4 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(1678.241 + 1681.229 + 1640.339 + 1643.277 + 1641.111) / 5 = $1656.8394 Mil.
Total Assets at the begining of this year (Sep23) was $1,678.2 Mil.
Long-Term Debt & Capital Lease Obligation was $402.1 Mil.
Total Current Assets was $590.2 Mil.
Total Current Liabilities was $296.4 Mil.
Net Income was -22.687 + -30.795 + -24.331 + -18.516 = $-96.3 Mil.

Revenue was 138.705 + 137.22 + 146.917 + 151.954 = $574.8 Mil.
Gross Profit was 56.825 + 54.814 + 59.891 + 62.311 = $233.8 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(1755.582 + 1740.034 + 1709.174 + 1695.108 + 1678.241) / 5 = $1715.6278 Mil.
Total Assets at the begining of last year (Sep22) was $1,755.6 Mil.
Long-Term Debt & Capital Lease Obligation was $599.5 Mil.
Total Current Assets was $587.0 Mil.
Total Current Liabilities was $92.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeoGenomics's current Net Income (TTM) was -77.7. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

NeoGenomics's current Cash Flow from Operations (TTM) was 15.0. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=-77.728/1678.241
=-0.04631516

ROA (Last Year)=Net Income/Total Assets (Sep22)
=-96.329/1755.582
=-0.05487012

NeoGenomics's return on assets of this year was -0.04631516. NeoGenomics's return on assets of last year was -0.05487012. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

NeoGenomics's current Net Income (TTM) was -77.7. NeoGenomics's current Cash Flow from Operations (TTM) was 15.0. ==> 15.0 > -77.7 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=402.128/1656.8394
=0.24270789

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=599.482/1715.6278
=0.34942427

NeoGenomics's gearing of this year was 0.24270789. NeoGenomics's gearing of last year was 0.34942427. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=590.241/296.406
=1.99132609

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=586.95/92.926
=6.31631621

NeoGenomics's current ratio of this year was 1.99132609. NeoGenomics's current ratio of last year was 6.31631621. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

NeoGenomics's number of shares in issue this year was 126.953. NeoGenomics's number of shares in issue last year was 125.687. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=280.431/644.118
=0.43537209

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=233.841/574.796
=0.40682433

NeoGenomics's gross margin of this year was 0.43537209. NeoGenomics's gross margin of last year was 0.40682433. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=644.118/1678.241
=0.38380542

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=574.796/1755.582
=0.32741051

NeoGenomics's asset turnover of this year was 0.38380542. NeoGenomics's asset turnover of last year was 0.32741051. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+0+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

NeoGenomics has an F-score of 6 indicating the company's financial situation is typical for a stable company.

NeoGenomics  (NAS:NEO) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


NeoGenomics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913